The CFTR gene encodes a chloride channel with pleiotropic effects on cell physiology and metabolism. Here we show that increasing cGMP levels to inhibit ENaC in CF respiratory epithelial cells corrects several aspects of the downstream pathology in CF. Cell culture models, using a range of CF cell lines and primary cells, showed that complementary pharmacological approaches to increasing intracellular cGMP, by elevating guanyl cyclase activity though NO·, addition of cell-permeable cGMP analogs, or inhibition of phosphodiesterase 5, corrected multiple aspects of the CF pathological cascade. These included correction of defective protein glycosylation, bacterial adherence and proinflammatory responses. Furthermore, pharmacological inhibition of phosphodiesterase 5 in tissues ex vivo or in animal models, improved transepithelial currents across nasal mucosae from transgenic F508del Cftr tm1Eur mice, and reduced neutrophil infiltration upon bacterial aerosol challenge in Pseudomonas aeruginosa-susceptible DBA/2 mice. Our findings define phosphodiesterase 5 as a specific target for correcting a number of previously disconnected defects in the CF respiratory tract, now linked through this study. Our study suggests that phosphodiesterase 5 inhibition provides an opportunity for simultaneous and concerted correction of seemingly disparate complications in CF.
INTRODUCTION
Cystic fibrosis (CF) is the most common life-shortening inheritable disease in Caucasians caused by mutations in the gene encoding cystic fibrosis transmembrane conductance regulator (CFTR) (41) . CFTR, apart from being a chloride channel (1) , confers pleiotropic effects on other cellular functions (26, 37) . The synergisms between CFTR and other systems have lead to a search for organ-specific modifier genes and factors, since the CFTR genotype alone does not always correlate with severity of respiratory disease (10, 14) .
Recent studies (31) unequivocally point to the pivotal role of a runaway sodium transport in CF lung pathology, secondary to the loss of epithelial sodium channel (ENaC) regulation in CFTR-mutant respiratory epithelial cells (46) . This defect is responsible for respiratory tract problems, including airway surface liquid hyperabsorption (31) and hyperacidification of the trans-Golgi network (TGN) in CF respiratory epithelial cells (38) , although the mechanism and signaling events linking upstream defects in CF and TGN hyperacidification remain to be delineated. The previously reported abnormally acidic TGN lumen in CF cells causes suboptimal sialyltransferase activity (38) , resulting in defective sialylation of plasma membrane glucoconjugates providing neoreceptors for bacterial adherence, thus promoting chronic bacterial colonization and inflammation in the CF lung (3, 7, 22, 38) . We have recently reported (39) our initial observations that hyperacidification of another intracellular compartment in CF cells, i.e. recycling endosome, is affected by cGMP levels and a phosphodiesterase activity, but the exact signaling pathway and specific components involved have not been identified.
Here we present siRNA knockdown-based experiments demonstrating directly that ENaC activity is responsible for organellar hyperacidification in CF cells, and show that phosphodiesterase 5 (PDE5) can be specifically targeted to normalize lumenal pH in the TGN of CF respiratory epithelial cells. We demonstrate the causal relationships in CF cells (see model in Fig. 1 ), starting with their reduced nitric oxide (NO·) levels, leading to lower than normal cGMP levels, and ending with the effects on hyperacidification in CF based on unrepressed ENaC due to lower cGMP levels. We furthermore show that the PDE5 inhibitor sildenafil corrects the majority of the known pathological defects in CF, by reducing bacterial adhesion to respiratory epithelial cells and normalizing the overexuberant proinflammatory response to bacterial products. Inhibition of PDE5 provides beneficial effects in ex vivo studies with respiratory mucosal tissue from transgenic mice and in an aerosol infection model with mice susceptible to Pseudomonas aeruginosa, the principal bacterial pathogen in CF.
METHODS
Chemicals. Sildenafil (2) was prepared by purification as previously described (16) and used at therapeutically relevant concentrations of 300 nM (http://www.viagramd.com) with pharmacokinetics not affected by azithromycin (35) , a drug frequently prescribed in CF. The following compounds were from BIOMOL Research Laboratories (PA): N-(3-(aminomethyl)benzyl)acetamidine (1400W), a highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo (18) 
, 2-(2-Propoxyphenyl)-8-azahypoxanthine (Zaprinast), 8-Br-cGMP and dibutyryl-cGMP. N-(benzylamidino)-3,5-diamino-6-chloropyrazine-carboxiamide (benzamil) was from Alexis. The specific CFTR chloride channel inhibitor CFTR inh -172 (30) was from A. Verkman.
-independent activator of NO .
-sensitive guanylyl cyclase (5) was from Sigma.
Cells and tissue culture. IB3-1 is a bronchial epithelial cell line derived from a CF patient with a DF508/W1282X CFTR mutant genotype (55). S9 is a derivative of IB3-1 corrected for chloride conductance by stable transfection with a functional CFTR. The cells were maintained in LHC-8 Media (Biosource Int., MD). The CF cell line CFBE41o-(DF508/DF508) and normal human bronchial epithelial cells16HBEo-(from D. Gruenert) were maintained in complete MEMmedia (GibcoBRL, Life Technologies, MD). The normal human tracheal cell line 9HTEo-, transfected with pCep-R or pCep were from P. Davis, and were maintained in complete DMEM (GibcoBRL, Life Technologies, MD). Primary bronchial epithelial cells were from Clonetics (NHBE) or from P. Karp (CF lung transplants) and were maintained in supplemented BEBM (Camberx, MD). CFTR genotyping was carried out by PCR and oligonucleotide ligation assay. Primary cells and multiple cell lines, as genetically or otherwise matched pairs (CF and normal phenotypes), when available, were used. The cell lines in this study represent nearly all published lines available and developed for CF research by independent groups, with the exceptions of: (i) CFT1 cells (36) as their culture requires cholera toxin added to the medium, and consequently were not included in this study; and (ii) CuFi cell lines (54), since these cells could not be used in our Pseudomonas adhesion assay as the monolayers were highly sensitive to addition of bacteria.
Transfections and microscopy. TGN38 fusion with pH sensitive GFP (33) was from J. Rothman. Cells were transfected with 1 Ng/ml DNA using Effectene (Qiagen, CA) for 48 h. Ratiometric pH determination by fluorescence microscopy in live cells was carried out as previously described (33, 38, 40) . A pH standard curve was generated by collapsing the pH-gradient by incubating cells in 10 mM monensin and 10 mM nigericin for 30 min at 37 o C in buffer A at pH 7.4, 6.5 or pH 5.5 and ratios were recorded for internal standards. Fluorescence images were taken upon excitation at 410 and 470 nm (6 consecutive exposures). Three regions of interest were selected and the standard curve was plotted as averaged 410/470 ratio values for a given buffer pH. The term hyperacidification for TGN in CF cells, is used relative to the less acidic pH in normal or CFTRcorrected cells. It is known that the pH of TGN is elevated in airway epithelial cells compared to a number of other cell types (49) . Confocal fluorescence microscopy of fixed samples was carried out on Zeiss 510 META microscope. Endogenous ENaC was revealed by immunoblots or immunofluorescence (ENaC antibody from Diagnostic Intl.).
Manipulation of signaling pathways affecting pH of TGN in CF cells. All compounds were diluted in buffer A prior to addition. NO-donors DETA-NONOate or NOR-4 were added for 20 min at a concentration, which initially released 0.1 mM NO . under physiological conditions. Nitric oxide synthase was inhibited in S9 cells by incubation with 1 mM L-NAME or R-NAME for 60 min. 10 mM of guanylin (28) or protoporphyrin IX (21) (guanylate cyclase activators) were added for 15 and 90 min respectively. 10 NM ODQ (51) or NS-2028 (8) (guanylate cyclase inhibitors) were added at for 30 min followed by incubation of the cells with DETA-NONOate, as described above. 100 NM 8-Br-cGMP (51) or dibutyrylcGMP (8) was added for 60 min, or 30 min respectively. Phosphodiesterase inhibitors, 200 NM IBMX (23), 100 nM MBCQ, 10 NM rolipram, 1 or 50 NM zaprinast and 300 nM sildenafil were added for 60 min at 37 o C. 10 NM acetylstrophantedine was added for 1 h prior to addition of 300 nM sildenafil. S9 cells were incubated with 0.6 NM CFTR inh -172 for 15 min followed by 3 washes with buffer A each wash for 10 min. To block intracellular ENaC, cells were treated for 60 min with 10 NM benzamil, a membrane permeate derivative of the sodium channel blocker amiloride.
ENaC-and PDE5 knockdown with siRNA. All siRNAs were from Dharmacon, generated using specific algorithms for exclusive targeting. Scrambled siRNAs were used as controls. Introduction of siRNA into the cells was by Effectene. Protein knockdown was monitored by immunoblotting.
Sialylation of GM1 in CF lung epithelial cells, P. aeruginosa adherence to CF lung epithelial cells, and NF-kB activation. aGM1 levels were assessed with fluorescently labeled cholera toxin, bacterial adhesion by colony counts, and NF-B activation by luciferase assays, as previously described (38) . CF and normal cells, grown post confluency, were incubated for 48 h with 50 NM zaprinast or 300 nM sildenafil. Cells were fixed and stained with fluorescently labeled cholera toxin B for 60 min at room temperature. Relative fluorescence was calculated from actual grey levels of 10 random fields from 3 independent experiments. Post-confluent cells, treated with 50 NM zaprinast or 300 nM sildenafil, were incubated with P. aeruginosa (PAO1) at a multiplicity of infection of 1:200 in MEM media without serum or antibiotic supplements. Samples were washed 3 times with PBS and lysed with 0.5% TX-100. Cell associated bacteria were plated on P. aeruginosa isolation agar and colonies counted. Treatment with Pseudomonas pro-inflammatory lipopeptide (lipotoxin) LptA and NF-B activation analysis were carried out as previously described (15) . Animal model of P. aeruginosa aerosol infection and myeloperoxidase levels in lung tissues. DBA/2 mice (6-8 weeks; Charles River Laboratories) were fed a specially-formulated diet with or without sildenafil: 600 g dry regular NIH mouse chow blended to coarse powder with sildenafil embedded in 1 % agar paste frozen in ice-cube trays. P. aeruginosa aerosol infection model was carried out as previously described (53) . Lung tissue-associated myeloperoxidase activity was measured in homogenized lung samples o-dianisidine hydrochloride oxidation assay (6) . One unit of MPO activity is defined as the decomposition of 1 Nmol of H 2 O 2 /min. Statistics. Unless otherwise specified, statistical analyses were carried out using Fisher's Protected LSD post hoc test (ANOVA) (SuperANOVA, Abacus Concepts).
Additional methods. This information is provided in Supplemental Materials.
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RESULTS
Hyperacidification of trans-Golgi network in CF respiratory epithelial cells is due to abnormally low iNOS and NO
. levels. The levels of NO· in the CF lung are lower than normal (19, 25, 32) . We tested the hypothesis that the NO . defect in CF respiratory epithelial cells contributes to TGN hyperacidification, via a NO .
-guanylate cyclase-cGMP cascade controlling sodium channel activity. The TGN pH was determined using the pH-sensitive GFP, as previously described (38), with Fig. 2A showing the characteristic perinuclear localization of the TGN38-pHlourin GFP probe to the TGN, in keeping with prior marker colocalization studies (38) . The CF lung epithelial cell line IB3-1 (55) lacking in Cl -donors DETA-NONOate and NOR-4. This normalized the pH in the TGN (DETA-NONOate: pH 7.0 ± 0.2; NOR-4: pH 6.9 ± 0.2) (Fig. 2E) . Conversely, when S9 cells were incubated with a NOS inhibitor L-NAME or a highly specific iNOS inhibitor 1400W, the TGN in S9 (CFTRcorrected) cells became hyperacidified, matching that of CF cells (Fig. 2F) . Treatment of cells with the inactive enantiomer, R-NAME, did not affect the TGN pH (Fig. 2F ). donor DETA-NONOate, both ODQ (pH 6.1 ± 0.1) and NS-2028 (pH 6.1 ± 0.2) counteracted normalization of TGN pH in response to DETA-NONOate (Fig. 2G) .
Stimulation with cGMP normalizes TGN pH in CF cells. We next tested whether cGMP can normalize the TGN pH in CF cells.
Two membrane permeant forms of cGMP, 8-Br-cGMP and dibutyryl-cGMP corrected the hyperacidification of TGN: the pH changed from 6.1 ± 0.1 to 6.9 ± 0.2 (for 8-BrcGMP) and to 6.8 ± 0.2 (for dibutyryl-cGMP) (Fig. 2H) . Collectively, these experiments connect the NO . deficiency in CF (19, 24, 32) to organellar hyperacidification in CF respiratory epithelial cells (9, 37, 38, 40) via a guanylate cyclase signaling pathway.
Cyclic
GMP-specific phosphodiesterase inhibitors correct TGN hyperacidification in CF. Based on these observations, inhibiting cellular phosphodiesterases and increasing intracellular cGMP appeared as a viable approach for pharmacological intervention in CF. Of the 11 recognized PDE families, 7 are expressed in the lung, including PDE1, PDE3-7 and PDE9 (4, 17) . The cGMP-specific PDE5 is abundant in the lung, and, along with the cAMPspecific PDE4 (20) , represents the predominant PDE form, accounting for nearly 80% of the overall PDE activity in the airways. When IB3-1 CF cells were treated with rolipram, an inhibitor specific for PDE4 (4, 17, 20) that hydrolyzes cAMP, no change in the TGN pH was observed (Fig. 3A) . Zaprinast, a precursor in the development of the drug sildenafil, an inhibitor of PDE5 (which hydrolyzes cGMP), corrected TGN hyperacidification from pH 6.1 ± 0.2 to 6.9 ± 0.1 (Fig. 3A) . At higher concentrations, zaprinast inhibits PDE6 and 9 (44) . Increasing zaprinast concentration lead to no additional change in pH relative to the PDE5-specific action at lower zaprinast concentrations (Fig. 3A) , thus suggesting that PDE6 and PDE9 had no dominant effect. The role of PDE5 was further confirmed by using a PDE5-inhibitor MBCQ, which corrected TGN hyperacidification in CF cells, from 6.1 ± 0.2 to 6.8 ± 0.1 (Fig. 3A) . IBMX, a nonselective PDE inhibitor, with added complexity of adenosine action, increased TGN pH from 6.1 ± 0.2 (untreated control) to 6.6 ± 0.3. The chloride channel activity of CFTR is readily activated by cAMP (46) , thus in this series of experiments we could not rule out that the effect with IBMX could be attributed to cAMP, rather than cGMP.
To confirm our pharmacological analyses, we established by immunoblotting that PDE5 is expressed in human bronchial epithelial cells (Fig.  S2) . Next, PDE5 knockdown using siRNA was performed. As predicted, PDE5 siRNA, but not a scrambled control siRNA, corrected TGN pH in IB3-1 cells (Fig.  3A , pH 6.7 ± 0.1 and 6.0 ± 0.1 respectively, p=0.0008). The results with PDEinhibitors were confirmed in additional cell lines. A tracheal epithelial cell line 9HTEo-, displaying CF phenotype due to the expression of a dominant negative CFTR construct (pCep-R) (7), was treated with zaprinast (Fig. 3B) . The TGN pH was corrected (6.3 ± 0.1 to pH 6.7 ± 0.2) and matched that in the normal control (9HTEo-cells transfected with the plasmid pCep without the CFTR R-domain).
Sildenafil efficiently corrects hyperacidification in primary human epithelial cells. Sildenafil has shown promise in clinical studies for treatment of lung disease, such as primary pulmonary hypertension (42, 45) . We tested this widely-used FDA-approved PDE5 inhibitor, with a 240-fold greater specificity towards PDE5 than zaprinast. Sildenafil, at therapeutically relevant concentrations of 300 nM normalized the TGN pH in IB3-1 cells matching that of the CFTR-corrected S9 cells (Fig. 3A, E-G) . The correction of TGN hyperacidification upon sildenafil treatment was confirmed in bronchial epithelial cell line CFBE41o-derived from a patient homozygous for QF508 CFTR mutation (32) (Fig. 3C) . Moreover, primary human bronchial epithelial cells (CFTR
F508/ F508
) obtained from lung transplants showed pH correction upon sildenafil treatment (Fig. 3D) .
Sodium transport via ENaC is responsible for TGN hyperacidification in CF.
We have previously demonstrated (37, 38) that increased Na + efflux from the TGN lumen in CF cells is responsible for the hyperacidification of this organelle in a CFTR-defective background (see model in Fig. 1) . In CF cells, the open probability of ENaC is increased, allowing efflux of Na + , which is delivered into the organellar lumen by Na (37, 38) . As a net result, the TGN lumen becomes hyperacidified in CF cells.
First, we confirmed that ENaC colocalizes with the TGN38-GFP probe (Fig. 4A-D) and is expressed at equal levels in CF and normal respiratory cells, as shown by immunoblots (Fig. 4E) . We established the sequential aspects of this model, which predicts that cGMP corrects TGN hyperacidification in CF cells via ENaC, since cGMP is a potent amiloride-sensitive sodium channel blocker (29). Sildenafil increased cGMP (Fig. 5A ), but not cAMP (Fig. 5B ) levels in primary CF lung epithelial cells. Inhibition of Na + ,K + -ATPase using the membrane-permeant inhibitor acetylstrophantedine (37, 38) induced hyperacidification in CFTRcorreced cells (Fig. 5C) . A membrane permeant inhibitor of ENaC, benzamil, corrected the TGN hyperacidification in IB3 cells (Fig. 5D ) and in primary CF cells homozygous for the QF508 CFTR allele (Fig. 5E) . Finally, we demonstrated that ENaC was responsible for these effects using ENaC-siRNA. ENaCknockdown (Fig. 5F ) corrected the pH of the TGN in IB3-1 cells (Fig. 5G) , whereas control siRNA treatment did not. In addition, we established that chloride channel activity of CFTR did not affect TGN pH, as inhibition of CFTR Cl -transport by a highly selective channel inhibitor, CFTR inh -172 (30), did not alter organellar pH in normal cells (Fig. 5H) .
Phosphodiesterase 5 inhibitor sildenafil corrects pathological cascade in CF epithelial cells. A candidate drug must be able to ameliorate a set of defined pathological abnormalities in CF. The disease-causing effects of TGN hyperacidification in CF are the characteristic undersialylation of plasma membrane glycoproteins and glycolipids and increased adhesion of CF pathogens, e.g. P. aeruginosa, to asialo-glycoconjugates (7, 11, 22, 27, 38) , which, at later stages of advanced disease, lead to P. aeruginosa association with the mucus (50). Zaprinast and sildenafil restored sialylation in IB3-1 cells to the levels seen in the CFTR-corrected S9 cells (Fig. 6A-C) . PDE5 inhibition also corrected sialylation in another tested CF cell line (CFBE41o-), restoring it to the levels seen in 16HBE14o-normal human bronchial cells (32) (Fig. 6C) . The effects of sildenafil could not be attributed to mislocalization of the sialyltransferase, since it remained in the TGN (Fig. 6D&E) . Thus, the correction of the sialylation defect is due to normalization of the pH at the appropriate site of sialyltransferase enzymatic action. PDE5 inhibitors also corrected P. aeruginosa adhesion to CF cells. Bacterial adherence to IB3-1 cells was reduced to the levels seen with the CFTRcorrected S9 cells (Fig. 6F) . CFBE41o-cells treated with sildenafil showed a 10-fold reduction of bacterial adhesion bringing it to levels comparable with normal bronchial cells (16HBE14o-) (Fig. 6G) . Similar reduction in P. aeruginosa adhesion was observed in 9HTEo -pCep-R cells treated with sildenafil (Fig. 6G) . Reduction of P. aeruginosa adhesion upon sildenafil treatment was confirmed in primary human QF508/QF508 bronchial epithelial cells (Fig. 6H) . Thus, pharmacological inhibition of PDE5 corrects both the sialylation and bacterial colonization defects associated with CF respiratory epithelial cells (3, 7, 22, 38) .
Another critical aspect of lung pathogenesis in CF is an over-exuberant inflammatory response to bacterial products such as P. aeruginosa pilin (12) and lipoproteins (15) . We tested the effect of PDE5 inhibition on NF B activation in response to Pseudomonas-derived proinflammatory lipopeptide LptA (15) . Incubation of IB3-1 cells (CF) with zaprinast or sildenafil reduced NF B activation to the control levels (Fig. 6I) . Thus, sildenafil corrects the excessive proinflammatory response in CF respiratory epithelial cells, in keeping with the observation that PDE5 inhibitors can reduce proinflammatory airway responses to LPS (47).
Sildenafil improves CFTR current.
In addition to analysis of TGN pH, we studied the effect of sildenafil in a mouse nasal potential difference model. In Ussing chamber short circuit current (Isc) studies, nasal mucosae from F508del Cftr tm1Eur mice, congenic FVB, were subjected to sildenafil treatment. Sildenafil, in the presence of amiloride, increased short circuit current in 5 out of 5 mice (10 nasal tissues) tested (QIsc=63±12; Fig. 7A ). The effect of sildenafil was most likely mediated via residual QF508 CFTR channels in F508del Cftr tm1Eur mice, since: (i) amiloride was present during sildenafil stimulation; (ii) the sildenafilinduced Isc response in F508del Cftr tm1Eur was sensitive to glibenclamide; and (iii) the Isc response to sildendafil was absent in null CFTR -/-transgenic mice (identical genetic background, FVB). Thus, sildenafil effects on mucosal tissues from QF508 CFTR congenic mice indicate further benefits of Sildenafil treatment, beyond the effects on organellar pH, by enhancing CFTR currents.
Sildenafil reduces neutrophil lung infiltration in mice aerogenously infected with P. aeruginosa. We tested the effects of sildenafil on relevant inflammatory parameters (neutrophil infiltration which is a principal cause of lung damage in CF) in an animal model of respiratory exposure to P. aeruginosa aerosols (52) using DBA/2 mice sensitive to P. aeruginosa (34) . No significant protection with sildenafil was detected against mortality in this model of acute infection (n=90, p=0.294; Log Rank test). Myeloperoxidase measurements showed reduction in neutrophil infiltrates by 42±11% (n=8; p=0.047, t-test) at 12 h post-exposure in sildenafil treated animals (Fig. 7B) . Effects on mortality in chronic infection (avoiding methods of artificially imposed chronic infection, e.g. by embedding bacteria in agar beads) could not be monitored, as mice either succumbed to naturally delivered acute infection or cleared P. aeruginosa rapidly form the lungs, as previously shown (52) .
DISCUSSION
The experiments reported here connect the hitherto disparate defects in CF: the lower than normal NO . levels (19, 25, 32) , and the Na + transport-dependent hyperacidification of the organellar lumen in CF (37, 38, 40) . This work demonstrates, using ENaC knockdowns, the cascade involving nitric oxide, cGMP, and ENaC in organellar hyperacidification and dysfunction in CF. This study, along with a recent indirect data indicating (39) that a similar pathway operates in the endosomal compartment in CF cells, establishes the cascade of signaling and physiological events explaining several of the principal pathological features in CF. As depicted in the model in Fig. 1 panel C, the lower than normal NO . levels in CF respiratory epithelial cells (19, 25, 32) cause suboptimal cGMP levels. The uninhibited ENaC, which is normally blocked by cGMP, results in enhanced Na , by stimulating guanylate cyclase using agonists, by increasing intracellular cGMP with membrane permeant cGMP analogues, or by incubating the cells with cGMP-specific phosphodiesterase inhibitors. These data also suggest that blocking ENaC by elevating intracellular cGMP may correct the molecular pathological cascade seen in CF lung epithelia cells.
Our recent report (39) suggests that inhibition of PDE5 corrects hyperacidification of recycling endosomes in CF cells in a similar fashion to the processes reported here. It is likely that the pertinent signaling pathways, delineated in the present study for the TGN, apply to other organelles in which ENaC and sodium fluxes play a role, including endosomes in CF respiratory epithelial cells (40) . Furthermore, a study by Dormer and colleagues has indicated that sildenafil affects QF508-CFTR localization in nasal epithelial cells (13) . The concentration of sildenafil used by Dormer et al., (13) , ranged from 150 NM for correction of CFTR trafficking to 1 mM for correction of chloride channel activity. This exceeds by far the more pharmacologically relevant concentrations used in our study (300 nM sildenafil) that match plasma levels achieved in standard sildenafil use in humans. Nevertheless, the previously published studies (13, 39) and the present work point to the potentially beneficial action of sildenafil in CF.
Our study demonstrates that pharmacological inhibition of PDE5 corrects a succession of interconnected defects in CF respiratory epithelial cells. Moreover, the pathological manifestations of the pH defect (37, 38, 40) are corrected by sildenafil treatment. This includes: (i) undersialylation of plasma membrane glycoconjugates, (ii) bacterial adhesion, (iii) excessive proinflammatory response, (iv) electrolyte transport across respiratory mucosa, and (v) lung inflammation in response to CF-specific bacterial pathogen. The observation that a sequence of abnormalities in CF can be connected as shown in the present study, indicates that a common root to the clinically relevant problems can be identified. It is equally important, that this chain of pathological consequences can be corrected or ameliorated by clinically proven PDE5 inhibitors. Since this can be achieved with low, therapeutic doses of Sildenafil as shown in the present study, our findings represent a step towards clinical trials with sildenafil in CF. D & E) fluorescence confocal microscopy of IB3-1 cells co-transfected with constructs expressing myc-tagged sialyltransferase (D) and TGN38-GFP (E) after treatment with 300 nM sildenafil, performed as previously described (38) . Inset, S9 cell. TGN-38-GFP and sialyltransferase remain colocalized as in untreated cells. F-H) PDE5 inhibition (50 NM zaprinast or 300 nM sildenafil) corrects bacterial adhesion. IB3-1 control, n=9; CF primary cells, n=6; all other experimental groups, n=11. I) NF-B signaling was measured using a promoter activation luciferase assay, following stimulation with P. aeruginosa proinflammatory lipopeptides (LptA) as described (15) . 50 NM zaprinast, n=3; 300 nM sildenafil, n=3. 
